Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02619253 · ClinicalTrials.gov registry record · Phase 1
Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma
A Phase 1 study, sponsored by Nabil Adra.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT02619253 is a Phase 1 study that has completed, run by Nabil Adra. The registered enrollment target is 52 participants.
The verdict
NCT02619253, a Phase 1 study, has completed, sponsored by Nabil Adra.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
Primary objective: To assess the early signals for anti-tumor activity (i.e. objective response rate, progression-free survival) of pembrolizumab in combination with vorinostat in patients with advanced prostate, renal or urothelial cell carcinoma. Secondary objectives: (1) To evaluate the overall safety profile of pembrolizumab in combination with vorinostat; (2) To assess the safety and tolerability of pembrolizumab in combination with vorinostat in patients with advanced prostate, renal or urothelial cell carcinoma in order to select the recommended Phase 2 Dose (RP2D)
Interventions
- DRUG Pembrolizumab
- DRUG Vorinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2016-02-23 |
| Est. Completion | 2023-03-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02619253
The ClinicalTrials.gov registry entry for NCT02619253 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nabil Adra, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02619253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02619253 about?
NCT02619253 is a clinical study titled "Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma". Primary objective: To assess the early signals for anti-tumor activity (i.e. objective response rate, progression-free survival) of pembrolizumab in combination with vorinostat in patients with advanced prostate, renal or urothelial cell carcinoma. Secondary objectives: (1) To evaluate the overall ...
What is the current status of trial NCT02619253?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2016-02-23. Estimated completion is 2023-03-28.
What interventions are being tested in trial NCT02619253?
The interventions under investigation include: Pembrolizumab (DRUG), Vorinostat (DRUG).
Who is sponsoring clinical trial NCT02619253?
This trial is sponsored by Nabil Adra, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.